[On blood coagulation disorders during enzyme therapy of malignant tumors and hemoblastoses].
D000230:Adenocarcinoma / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D001792:Blood Platelets / Q000187:drug effects; D001859:Bone Neoplasms / Q000188:drug therapy; D002648:Child; D002830:Choroid Neoplasms / Q000188:drug therapy; D005165:Factor V / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D010954:Plasmacytoma / Q000188:drug therapy; D013916:Thrombelastography
D005165:Factor V; D005169:Factor VIII; D005340:Fibrinogen; D001215:Asparaginase
Uber Störungen des Blutgerinnungssystems im Verlaufe der Enzym-Therapie maligner Tumoren und Hämoblastosen.